What exeltis germany does

Exeltis Germany GmbH is a pharmaceutical company headquartered in Ismaning, Germany, that commercializes originator and generic women's health products across the entire female life cycle from menarche to menopause. Founded in 2010 under the name Velvian, the company now markets more than 30 branded prescription and OTC products covering contraception (oral tablets, the GinoRing vaginal ring, emergency contraception, and the delayed-release Kelzy oral contraceptive), fertility and pregnancy (the Xonvea two-phase doxylamine/pyridoxine formulation for nausea, plus nutritional supplements Clavella, Velnatal, and FOLANDROL), menopause hormone therapy (FAMENITA micronized progesterone, DERMESTRIL transdermal patches, VELBIENNE), and urogenital/specialty care (DeflaGyn oxidative gel for HPV-associated cervical dysplasia, GELIFEND, FENIZOLAN, Pravidel), as well as endometriosis (ENDOVELLE) and PCOS hirsutism (Kelzy). Underlying technologies include novel drug-delivery architectures such as the sustained-release retard oral tablet and the two-phase release combination formulation, both classified as proprietary method architectures.

The company operates a B2B2C distribution model in which a field sales force (Außendienst) targets prescribing gynecologists in the outpatient sector, driving prescription pull-through to German pharmacies that dispense the majority of revenue (over 50% now derived from originator products). A secondary direct-to-consumer channel is operated through exeltis.de/shop, which uses ApoNow GmbH to route non-prescription and supplement orders to local pharmacies for fulfillment. Exeltis also operates the reflec:T, MEET & LEARN, and LEARN & PRACTISE digital continuing-education programs that deliver CME-certified women's health training to thousands of medical professionals annually, in cooperation with Sanabeo Medical News, Keck Media, and DocCheck.

Exeltis Germany is a wholly-owned subsidiary of the family-owned Insud Pharma Group, which employs more than 9,000 people across over 50 sites globally and encompasses API manufacturing (Chemo), generics (Xiromed), and biosimilars (mAbxience). The German subsidiary employs over 100 people across commercial, medical, sales, marketing, finance, HR, technical, and regulatory functions, and was reported by General Manager Jan Tangermann to have doubled revenue over approximately 2.5 years. Exeltis Germany serves the DACH region through offices in Ismaning (Germany) and Vienna (Austria).

Name

exeltis germany

Legal name

Exeltis Germany GmbH

Website

https://exeltis.de

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Exeltis Germany is a DACH-region pharmaceutical company specializing in women's health prescription and OTC products across contraception, fertility, pregnancy, menopause, and urogenital care, distributing through a gynecology field sales force, pharmacies, and a DTC e-commerce shop, with over 30 brands and a strategic pivot toward originator products.

Ownership category

akta.pro rank

Headquarters

HQ city

Ismaning

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D, Infrastructure

Revenue model

1. Prescription pharmaceutical products: Exeltis generates the majority of its revenue from prescription (rezeptpflichtig) pharmaceutical products sold through pharmacies and prescribed by gynecologists. Over 50% of revenue now comes from originator/original products.
2. Over-the-counter (OTC) and pharmacy-exclusive products: Certain products such as Femke (emergency contraception) are available without prescription (rezeptfrei), while others like Clavella Classic are pharmacy-exclusive (apothekenexklusiv), sold directly through the Exeltis shop and dispensed via partner pharmacies.
3. Nutritional supplements: Products such as Velnatal (Baby Planning, Pregnancy & Lactation), Clavella (Classic and Premium), and FOLANDROL are sold as dietary supplements, available directly through the Exeltis shop e-commerce channel.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Exeltis Germany distributes and markets a portfolio of pharmaceutical products focused on women's health across all life stages, spanning contraception, fertility and pregnancy, urogenital health, menopause, endometriosis, and PCOS-related indications. The company sells through pharmacies and gynecologists across the DACH region (Germany, Austria, Switzerland), supported by a field sales force, and operates the ApoNow online shop for OTC women's health products.

Product overview

Exeltis Germany is a pharmaceutical company specializing in women's health products across the entire female lifecycle from menarche to menopause and beyond. The portfolio includes over 30 branded products organized into six therapeutic areas: contraception (hormonal contraceptives including oral tablets like ASUMATE®, Evaluna®, Slinda®, Kelzy®; vaginal ring GinoRing®; emergency contraception Femke®), fertility and pregnancy (XONVEA® for pregnancy nausea, nutritional supplements Clavella® Classic/Premium, Velnatal® Babyplanung, Velnatal® Schwangerschaft + Stillzeit, FOLANDROL® for men), urogenital health and specialty care (DeflaGyn®, GELIFEND®, FENIZOLAN®, Agnolyt® MADAUS Tinktur, Pravidel®), endometriosis (ENDOVELLE®), hirsutism in PCOS (Kelzy®), and menopause hormone therapy (FAMENITA® micronized progesterone, DERMESTRIL® transdermal patches, VELBIENNE®). The company also provides healthcare professional services including the reflec:T continuing education platform with CME-certified webinars, MEET & LEARN training series, and LEARN & PRACTISE modules for practice staff.

Differentiator

Problem solved

Functional benefit

Products and services

• Contraception portfolio (oral tablets, vaginal rings, emergency contraception)
• Fertility and pregnancy product line
• Urogenital health products
• Menopause product line
• Endometriosis treatment product line
• PCOS / hirsutism treatment product line
• GinoRing (vaginal contraceptive ring)
• Kelzy retard
• Xonvea two-phase
• Slinda 24/4

Quantifiable outcome

• Over 50% of revenue from originator/original products (shifted from generics-focused)
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Sanabeo Medical NewscoreStrategic or Co-development Partner · 1 January 2025Sanabeo Medical News is the provider of CME-certified state-of-the-art training programs and is the core partner for Exeltis's reflec:T digital education initiative, which reaches thousands of medical professionals annually with product-neutral, practice-oriented continuing education in women's health.
• Keck MediacoreGTM or Marketing Partner · 1 January 2025Keck Media provides the webinar platform for Exeltis's MEET & LEARN endocrine training series for gynecology practice teams. Webinars are free for participants and include a certificate of attendance.
• Dr. med. Matthias Krick (MVZ Moers)minorStrategic or Co-development Partner · 1 January 2025Dr. med. Matthias Krick from MVZ Moers collaborated with Exeltis to develop the LEARN & PRACTISE training series for medical assistants (MFAs) in gynecological practices, covering practice management, organization, patient communication, and quality management.
• ApoNow GmbHminorChannel Partner/ Reseller/ Distributor · 1 January 2025ApoNow GmbH powers the pharmacy finder and fulfillment logistics for Exeltis's online shop. Patients can order supplements and OTC products for home delivery or same-day pharmacy pickup through the ApoNow platform.
• DocCheck CommunitycoreTechnology or Integration · 1 January 2025DocCheck provides the login and authentication system for Exeltis's Fachkreise (professional healthcare) portal. Per German Heilmittelwerbegesetz (HWG), certain website content is restricted to verified medical-pharmaceutical professionals. DocCheck verifies credentials before granting access.
• Mundo Sano FoundationminorOthers · 1 January 1993Mundo Sano is a family-run foundation founded in 1993 by Dr. Roberto Gold, dedicated to fighting neglected diseases and improving the lives of affected people. It is referenced on the Exeltis website as a shared commitment to global health improvement.
• Insud Pharma Group (Parent Company)coreStrategic or Co-development Partner · 1 January 1977Insud Pharma Group is the family-owned parent company of Exeltis, founded in 1977 by biochemist Silvia Gold and physician Hugo Sigman. The Group encompasses the full pharmaceutical value chain including API development (Chemo), biotech/biosimilars (mAbxience), generics (Xiromed), and the Exeltis commercial unit. Exeltis is the global commercialization and distribution unit focused on women's health, endocrinology, and CNS. The Group employs over 9,000 people at more than 50 sites globally. Today led by Leandro and Lucas Sigman.
• Chemo (Part of Insud Pharma Group)coreStrategic or Co-development PartnerChemo develops and manufactures pharmaceutical active ingredients (APIs), generic medicines, and novel galenic formulations. It is the scientific and technological backbone of the Insud Pharma Group, operating its own R&D departments for new molecules and innovative dosage forms, with over 60 manufacturing and research facilities globally and thousands of patents and patent applications.
• Xiromed (Part of Insud Pharma Group)coreChannel Partner/ Reseller/ DistributorXiromed is the Insud Pharma Group's generics division, particularly active in Europe and the USA with its own regulatory and distribution units, complementing the portfolio with generic solutions across multiple indications.
• mAbxience (Part of Insud Pharma Group)coreStrategic or Co-development PartnermAbxience develops and produces biopharmaceutical active ingredients and biosimilars, focused on oncology and autoimmune diseases, with production facilities in Spain, Argentina, and the USA. Part of the Insud Pharma integrated network supporting Exeltis.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Jenapharm: Jenapharm is the German women's health pharmaceutical subsidiary of Aspen Pharmacare, offering a comparable portfolio of hormonal contraceptives, HRT products, and gynecological treatments prescribed by gynecologists in Germany. Direct overlap with Exeltis on contraception (oral pills, vaginal rings) and menopause hormone therapy in the DACH region.
• Organon & Co. Organon is a global specialty women's health company spun out of Merck, with a comparable portfolio in contraception (e.g., NuvaRing), fertility, and menopause. Operates with a similar field sales model targeting gynecologists and is the most direct large-scale specialty peer to Exeltis's originator-focused strategy.
• Gedeon Richter Pharma: Gedeon Richter is a European specialty pharmaceutical company with a strong women's health portfolio including contraception, fertility, and menopause products sold across Europe including Germany. Highly comparable originator and generics mix, with similar field-force distribution through pharmacies.
• Theramex: Theramex is a global specialty women's health company focused on contraception, menopause, and fertility, sold through prescription and OTC channels in Europe. Closely comparable to Exeltis in therapeutic focus, originator/specialty positioning, and reliance on the gynecologist prescriber channel.
• Aristo Pharma: Aristo Pharma is a German pharmaceutical company with a strong generics portfolio that overlaps directly with Exeltis's contraceptive pills, HRT, and gynecological generics. Direct competitor in pharmacy-channel generics pricing and prescriber relationships.

Broad incumbents

• Bayer (Pharmaceuticals / Women's Health): Bayer is a broad incumbent whose pharmaceutical division competes directly in contraception (Yasmin/YAZ, Mirena IUD), menopause, and gynecological care. It has substantially larger R&D, marketing budgets, and global reach, but only women's health is one of multiple therapeutic franchises.
• Stada Arzneimittel: Stada is a German-based generic and specialty pharmaceutical company with significant DACH presence, including in women's health (e.g., contraceptive pills, HRT). It is a broader portfolio incumbent that competes across Exeltis's categories in Germany.
• Hexal (Sandoz): Hexal is the German generics arm of Sandoz, the global generics leader. It competes directly with Exeltis's contraceptive and HRT generics through pharmacy channels and statutory insurance reimbursement tenders in Germany.
• Sanofi (Women's Health / HRT): Sanofi operates a global women's health franchise (including menopause therapies and Dupixent in gynecological indications). It is a broad incumbent with substantially larger resources and competes with Exeltis in the gynecologist-prescribed specialty space.

Regional players

• Dermapharm Holding SE: Dermapharm is a German pharmaceutical company with a strong portfolio in dermatology, gynecology, and hormonal products. It competes in overlapping DACH channels, particularly in prescription gynecological and dermatological products sold through pharmacies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/exeltis-germany

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about exeltis germany